Health Archive » January, 2008

Health - January, 2008

175 articles

• Judge Corrects Claim Order In Medtronic Stent Case
• $1B Deal On Zyprexa Still May Not End Lilly's Woes
• Wyeth Victory In Prempro Lawsuit Survives Appeal
• Professor Raises Antitrust Issue In Vioxx Agreement
• Benefits Of ADEA Exemption Rule
• Lawyers In Guidant MDL Spar Over $45M Fee Request
• Chinese Producer Of Abortion Pill Under Investigation
• Crowell & Moring Nets Ex-FTC Attorney
• FDA Chastises Novartis Unit Over Safety Issues
• Sonnenschein Lures Litigator From Locke Lord
• Criminal Prosecution Of Off-Label Drug Promotion
• Hernia Patch Plaintiffs Play Hardball Over Names
• Wyeth Launches Generic Protonix To Preempt Rivals
• Floridians Wrongly Shut Out Of Vioxx Deal: Lawyers
• Nigerian Case Against Pfizer Runs Into Delay
• Patent Case V. Stryker Has Merit: Federal Circuit
• Fosamax Judge Tosses Leftover Class Action Claims
• Upsher-Smith's ANDA Spurs Another Suit From Forest
• MSJ Based On Motor Carrier FLSA Exemption Fails
• Bausch & Lomb ReNu Tests Were Flawed: Study
• Calif. Brings $1.6B Suit Against UnitedHealth
• Synthes Knowingly Sold Faulty Bone Implants: Suit
• States To Investigate Vytorin Marketing Ploys
• Lawmakers Subpoena FDA, HHS Head In Ketec Probe
• FDA Must Step Up Medical Device Scrutiny: GAO
• Court Nixes J&J's Bid To Toss Stent Patent Suits
• AARP, FTC File Amicus Briefs In Cipro Case
• Product Safety Initiative Should Go Global: FDA
• Impax's ANDA For Generic Painkiller Spurs Suit
• Baxter Recalls Heparin Doses
• Cordis Yanks Catheters Over Potentially Fatal Flaw
• Plaintiffs Push For Trial Date In AWP Lawsuit
• Glaxo Won't Block Generic Of Zantac Syrup
• Allergan Punches Back At Botox Death Claims
• Forest Labs Sues Six More Companies Over Namenda
• Apotex Gets $5M In Ear-Drop Patent Suit
• Plaintiffs Scoff At Pfizer's Experts On Viagra Safety
• Bayer Recalls Liquid Leukine For Adverse Effects
• Physician Arrangements Get Device Makers In Trouble
• Unauthorized Work Is Still Work: 2nd Circ.
• As FDA Review Looms, Drug Cos. Defend Vytorin Study
• $6.6M Awarded To Oculus In Trade Secret Suit
• PTO Rejects Gilead's Patents For HIV Drug
• Seroquel Plaintiffs Move To Quiz AstraZeneca's Drs.
• Vendors, Law Firms Clash Over E-Discovery
• FDA Removes Teeth From Exclusivity Forfeiture
• District Court Dismisses Tyco Antitrust Suit
• Lawmakers Urge FDA To Rethink Drug Labeling
• Mylan Hit With $69.2M In Treble Damages
• Lawmaker Wants Details On Rule For Drug Marketing
• Study Links Nexavar To Hypertension Risk
• Pregnant Pause In Barr-J&J Contraceptive Dispute
• J&J Battles Consolidation Of Ortho-Evra Lawsuits
• Merck, Schering Suspend TV Ads Touting Vytorin
• Judge Nixes Doctor Chats In Hernia Patch Case
• Home Care Co. Hit With Wage-And-Hour Suit
• Lawmakers Blast Bush For Cutting 9/11 Health Plan
• Stryker Yanks Hip Implants After FDA Scolding
• Manufacturer Expands Contaminated Syringe Recall
• Judge May Oust 426 Plaintiffs From Baycol MDL
• Novartis, Dr. Reddy's Deal Ends Exelon MDL
• Wyeth, Teva Persevere In Talks On Protonix Generic
• Retractable's Antitrust, Patent Claims Severed
• Judge Lays Out Prempro Case Timetable
• Just Ahead Of Patent Hearing, TVS Files For Ch. 11
• EU Pharma Probe Expected To Veer From FTC Course
• Ranbaxy Settles With GSK Over Generic Migraine Drug
• Pfizer Updates Chantix Label To Cite Possible Risks
• Eye Surgery Co., Sales Reps Settle Trade Secrets Row
• FDA Aims To Bolster Oversight Of Drug Safety Data
• AstraZeneca Sues To Block Generic Nexium
• High Court Agrees To Hear Wyeth Drug-Labeling Case
• Sanofi Loses Bid To Dismiss Claims Over Arava
• Effects Of China-U.S. Safety Pact On U.S. Companies
• Amgen Under Scrutiny Over Enbrel Marketing
• Bill Would Require That Health Plans Cover Autism
• Judge Grants 30-Day Stay To Negotiating Pharma Cos.
• Patent-Granting System Awaits Serious Shake-Up
• EC Raids Spike Plaintiffs' Interests, But No Suits Yet
• FDA Issues Stiff Warning On Child Cold Medicine
• 1st Circ. Won't Hear CytoLogix's Patent Claims
• Hep C Test Injunction Against Abbott Reversed
• Patent Act Won't Meet "Efficiency" Goals: Sources
• Antidepressant Makers Under Fire For Hiding Data
• FDA's CBE Codification Could Help Defendants
• Summary Judgment Denied In Applera Patent Saga
• Senate Bill May Do Damage to Damages: Sources
• FDA Proposes Stricter Rules On Drug Label Changes
• CryoCor Launches Two Cardiac Device Patent Suits
• Will The New EPA Rule Improve Hospital Air Quality?
• Impax Seeks To Pop Pimple-Fighting Patent
• Device Debris Left In Patients Poses Peril: FDA
• Stryker Wins Dismissal Of Squeaky Hip Implant Case
• Vytorin And Zetia Draw Suits And Scrutiny
• FDA Shakes Head At Stryker's Plant Practices
• Wyeth Fails In Bid To Dismiss Prempro Claim
• Merck Bullish On Vioxx Deal As Deadline Passes
• No Gain For Pain Of Wrongful Death: N.J. Governor
• AWP Plaintiffs Appeal Disqualification Of Counsel
• Diomed Denied Bid To Hold Cos. In Contempt
• As Special Master, She Sets Precedent
• Top Drugmakers Caught In EU Antitrust Raids
• Schering-Plough Settlement OK'd, Lawyers Get $9.5M
• The OIG's Opinion On Warehouse Club Programs
• Federal Preemption Upheld In Heart Valve Case
• Patent Reform Inches Closer To Passage
• Justices Weigh Whether To Hear Preemption Case
• Freedom Of Speech, PDIIs: A Recent Ruling In Maine
• Pfizer And Plaintiffs Fight Over Experts In Viagra Case
• Plea To Leapfrog FDA's Drug Rules Denied Cert
• High-Volume Patent Procurement May Cost More
• Federal Circuit Delivers Blow To Tranquil
• Thimerosal Testimony Barred In Wyeth Vaccine Case
• Pfizer Suffers Setback In Lipitor Patent Re-Exam
• Antitrust Claims Dismissed From HPV Patent Suit
• CMS's Question: To Revise Or Not To Revise
• Merck Inks Deal For Generic Fosamax: Report
• Usana Cleared By SEC, Still Faces Shareholder Suits
• Novartis, 2 Drug Cos. Strike Deal On Trileptal Patent
• Eli Lilly Resumes Gemzar Patent Claim Against Mayne
• Ex-Pfizer Director Granted Bail In Nigeria Drug Case
• Aetna Sues Express Scripts For Return Of $75M
• Calif. Justices, Eyeing Leave Act, Lean Toward Boss
• Celebrex Plaintiffs Suffer Blow In Evidence Spat
• City Scores In Employer-Funded Health Care Battle
• Pfizer Wins Dismissal Of Lipitor Class Action
• Court Refuses To Toss Enzo Shareholder Suit
• Boston Scientific Settles Merger Fight
• Sales Reps Target Solvay With Wage-And-Hour Suit
• Affymetrix, Illumina Strike $90M Settlement Pact
• Judge Nixes Proposed Class Action Against Roche
• N.J. Awaits Governor's OK On Wrongful Death Suit Bill
• Patent Litigator Healey Joins Kenyon & Kenyon LLP
• Foreign Investor Leads Class Action V. Drug Co.
• Medtronic Trade Secrets Suit Back In State Court
• Teva Drops Patent Suit Against Taro Over Heart Drug
• In Employment, Peer Review Privilege Is Not Absolute
• FDA Targets Pharmacies' Hormone Drug Marketing
• Pharmacies May Tread On FDA Turf With HRTs
• Bayer Must Answer Schering Stockholder Query: Court
• Lawmakers Leery Of Heart Doc's TV Plug For Lipitor
• Calif. Study Fails To Find Autism-Vaccine Link
• Growing "Cosmeceutical" Industry Faces Liability
• Judge Finds Purdue's OxyContin Patents Enforceable
• King, CorePharma Settle Skelaxin Suit
• Bristol-Myers Again Rebuffs Plavix Fraud Claims
• TV Ads Minimize Drug Risks: Study
• Applied Medical In-House Counsel Joins Crowell
• Appeals Win, But Maybe Not Cash, For Cordis
• Jan Marini Discontinues Second Eyelash Product
• American Medical Systems Owes $13.8M, Loses CEO
• Court To Reconsider Post-Claim Underwriting Class
• J&J Insists Manufacturer Infringed Neosporin Mark
• CMS Changes Will Curb Profits For Pod, Condo Labs
• Attys Gripe At Vioxx Deal's All-Or-Nobody Provision
• More Evidence Of Anemia Drug Risk: FDA
• Appeals Court Upholds $16M Judgment Against Q-Ray
• Plaintiffs' Attorney Kicked Off AWP Case
• Encysive, Glaxo Target Barr For Blood Clotting Generic
• Hogan & Hartson Adds Partner To Pharma Practice
• Merck Scores As Judge Spurns New Fosamax Class
• Pfizer Loses Lipitor Dispute In Canadian Court
• FDA May Pay Foes' Lawyers In Transplant Dispute
• EEOC Rule On Medicare Stirs Controversy
• Suit Says Sanofi Held Back Info On Obesity Drug
• Activists Sue FDA For Black Box Antibiotic Warnings
• Kinetic Group Sucked Into Suit Over Vacuum Device
• Coughlin Stoia Cashes In On Cardinal Case
• AstraZeneca Slams Seroquel Special Master's Report
• Medtronic Divvies Up $114M To Wind Down Suits
• AstraZeneca Sues Mylan Over Crestor Patent
• Judge Throws UnitedHealth Deal Into Jeopardy
• Drug Giants Probed Over U.N. Oil-For-Food Kickbacks
• Tyco Fires Back In Containers Case
• Judge Seeks Zyprexa Litigation Cleanup